"Inflammatory" breast cancer.

[1]  C. Ewing,et al.  Sentinel lymphadenectomy after neoadjuvant chemotherapy for breast cancer may reliably represent the axilla except for inflammatory breast cancer , 2002, Annals of Surgical Oncology.

[2]  S. Singletary,et al.  Effectiveness of mastectomy by response to induction chemotherapy for control in inflammatory breast carcinoma , 1997, Annals of Surgical Oncology.

[3]  S. Allan,et al.  Evolving treatment strategies for inflammatory breast cancer: a population-based survival analysis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Daniel Birnbaum,et al.  Gene expression profiling identifies molecular subtypes of inflammatory breast cancer. , 2005, Cancer research.

[5]  F. Bertucci,et al.  Gene Expression Profiling for Molecular Characterization of Inflammatory Breast Cancer and Prediction of Response to Chemotherapy , 2004, Cancer Research.

[6]  Rosette Lidereau,et al.  Molecular Profiling of Inflammatory Breast Cancer , 2004, Clinical Cancer Research.

[7]  G. Hortobagyi,et al.  p53 Expression as a Prognostic Marker in Inflammatory Breast Cancer , 2004, Clinical Cancer Research.

[8]  M. Dowsett,et al.  High incidence of HER-2 positivity in inflammatory breast cancer. , 2004, Breast.

[9]  P. Wingo,et al.  Population-Based Statistics for Women Diagnosed with Inflammatory Breast Cancer (United States) , 2004, Cancer Causes & Control.

[10]  F. Bertucci,et al.  Immunophenotypic analysis of inflammatory breast cancers: identification of an ‘inflammatory signature’ , 2004, The Journal of pathology.

[11]  G. Hortobagyi,et al.  Inflammatory breast carcinoma: the sphinx of breast cancer research. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  G. Hortobagyi,et al.  Inflammatory carcinoma of the breast: results of a combined-modality approach — M. D. Anderson Cancer Center experience , 1990, Cancer Chemotherapy and Pharmacology.

[13]  G. Bonadonna,et al.  Combined chemotherapy-radiotherapy approach in locally advanced (T3b-T4) breast cancer , 2004, Cancer Chemotherapy and Pharmacology.

[14]  M. Espié,et al.  Two prognostic groups of inflammatory breast cancer have distinct genotypes. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[15]  G. Hortobagyi,et al.  Inflammatory breast cancer: Clinical progress and the main problems that must be addressed , 2003, Breast Cancer Research.

[16]  W. Anderson,et al.  Inflammatory breast carcinoma and noninflammatory locally advanced breast carcinoma: distinct clinicopathologic entities? , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  G. Hortobagyi,et al.  Update on the management of inflammatory breast cancer. , 2003, The oncologist.

[18]  E. van Marck,et al.  Inflammatory breast cancer shows angiogenesis with high endothelial proliferation rate and strong E-cadherin expression , 2003, British Journal of Cancer.

[19]  M. Piccart,et al.  Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAKK multicenter study. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  D. Schultz,et al.  Ten-year outcome after combined modality therapy for inflammatory breast cancer. , 2003, International journal of radiation oncology, biology, physics.

[21]  M. Espié,et al.  Increased incidence of ERBB2 overexpression and TP53 mutation in inflammatory breast cancer , 2002, Oncogene.

[22]  M. Shibuya,et al.  Tumor‐infiltrating endothelial cells and endothelial precursor cells in inflammatory breast cancer , 2002, International journal of cancer.

[23]  S. Barsky,et al.  Cooperative role of E-cadherin and sialyl-Lewis X/A-deficient MUC1 in the passive dissemination of tumor emboli in inflammatory breast carcinoma , 2002, Oncogene.

[24]  S. Merajver,et al.  WISP3 is a novel tumor suppressor gene of inflammatory breast cancer , 2002, Oncogene.

[25]  S. Merajver,et al.  RhoC GTPase, a novel transforming oncogene for human mammary epithelial cells that partially recapitulates the inflammatory breast cancer phenotype. , 2000, Cancer research.

[26]  S. Merajver,et al.  RhoC GTPase overexpression modulates induction of angiogenic factors in breast cells. , 2000, Neoplasia.

[27]  S. Ebbs,et al.  Multimodality therapy in inflammatory breast cancer: is there a place for surgery? , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[28]  S. Merajver,et al.  Molecular biology of breast cancer metastasis: Inflammatory breast cancer: clinical syndrome and molecular determinants , 2000, Breast Cancer Research.

[29]  G. Somlo,et al.  Esthetic reconstruction after mastectomy for inflammatory breast cancer: is it worthwhile? , 2000, Journal of the American College of Surgeons.

[30]  S. Hellman,et al.  Separating favorable from unfavorable prognostic markers in breast cancer: the role of E-cadherin. , 2000, Cancer research.

[31]  S. Barsky,et al.  A novel human xenograft model of inflammatory breast cancer. , 1999, Cancer research.

[32]  S. Merajver,et al.  A novel putative low-affinity insulin-like growth factor-binding protein, LIBC (lost in inflammatory breast cancer), and RhoC GTPase correlate with the inflammatory breast cancer phenotype. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[33]  T. Odom-Maryon,et al.  Beyond Palliative Mastectomy in Inflammatory Breast Cancer—A Reassessment of Margin Status , 1999, Annals of Surgical Oncology.

[34]  A. Buzdar,et al.  Inflammatory breast carcinoma incidence and survival , 1998, Cancer.

[35]  J. Wagstaff,et al.  Management of Stage III Breast Cancer , 1998, Oncology.

[36]  G. Hortobagyi,et al.  Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D. Anderson Cancer Center , 1997, Cancer Chemotherapy and Pharmacology.

[37]  J. Kononen,et al.  Reduced E-cadherin expression is associated with invasiveness and unfavorable prognosis in breast cancer. , 1996, American journal of clinical pathology.

[38]  M. J. Lopez,et al.  Inflammatory breast cancer. , 1996, The Surgical clinics of North America.

[39]  S. Romain,et al.  Inflammatory carcinomas of the breast: A clinical, pathological, or a clinical and pathological definition? , 1995, International journal of cancer.

[40]  M. Lockett,et al.  Management of locally advanced carcinoma of the breast: II. Inflammatory carcinoma , 1994, Cancer.

[41]  B. Asselain,et al.  Prognostic factors in inflammatory breast cancer and therapeutic implications. , 1994, European journal of cancer.

[42]  A. Levine,et al.  Poor prognosis of p53 gene mutation and nuclear overexpression of p53 protein in inflammatory breast carcinoma. , 1993, Journal of the National Cancer Institute.

[43]  M. Takeichi,et al.  Expression of E-cadherin cell adhesion molecules in human breast cancer tissues and its relationship to metastasis. , 1993, Cancer research.

[44]  J. Julien,et al.  The Centre H. Becquerel studies in inflammatory non metastatic breast cancer. Combined modality approach in 178 patients. , 1993, British Journal of Cancer.

[45]  P. Levine,et al.  Ten-year results utilizing chemotherapy as primary treatment in nonmetastatic, rapidly progressing breast cancer. , 1993, Cancer investigation.

[46]  A. Levine,et al.  Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[47]  G. Hortobagyi,et al.  Inflammatory breast cancer: a review. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  D. Venzon,et al.  The effect of systemic therapy on local-regional control in locally advanced breast cancer. , 1992, International journal of radiation oncology, biology, physics.

[49]  D. Jaeck,et al.  Results of initial doxorubicin, 5‐fluorouracil, and cyclophosphamide combination chemotherapy for inflammatory carcinoma of the breast , 1990, Cancer.

[50]  F. Collins,et al.  Mutations in the p53 gene occur in diverse human tumour types , 1989, Nature.

[51]  S. Tommasi,et al.  Cell kinetics and hormonal receptor status in inflammatory breast carcinoma. Comparison with locally advanced disease , 1989, Cancer.

[52]  B. Asselain,et al.  Inflammatory breast cancer. Determination of prognostic factors by univariate and multivariate analysis , 1987, Cancer.

[53]  M. Forni,et al.  Surgery as part of a combined modality approach for inflammatory breast carcinoma , 1987 .

[54]  S. Friedman,et al.  Primary chemotherapy in the treatment of inflammatory breast carcinoma: a study of 230 cases from the Institut Gustave-Roussy. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  L. R. Hill,et al.  Inflammatory breast carcinoma: A distinct entity? , 1985, Journal of surgical oncology.

[56]  P. Levine,et al.  Inflammatory breast cancer: the experience of the surveillance, epidemiology, and end results (SEER) program. , 1985, Journal of the National Cancer Institute.

[57]  G. Blijham,et al.  Primary chemotherapy in cancer medicine , 1985 .

[58]  P. Hurteloup,et al.  Preoperative chemotherapy in the treatment of inflammatory breast cancer. , 1985, Progress in clinical and biological research.

[59]  D. Morris.  Mastectomy in the management of patients with inflammatory breast cancer , 1983, Journal of surgical oncology.

[60]  M. Pawlicki,et al.  Results of Combined Treatment of Patients with Locally Advanced Breast Cancer , 1983, Tumori.

[61]  P. Levine,et al.  Preliminary results of primary systemic chemotherapy in association with surgery or radiotherapy in rapidly progressing breast cancer , 1982, British Journal of Cancer.

[62]  G. Contesso,et al.  Frontiersman of Science , 1994, Environmental Health Perspectives.

[63]  G. Hortobagyi,et al.  Management of inflammatory carcinoma of breast with combined modality approach—an update , 1981, Cancer.

[64]  W. Wood,et al.  Inflammatory breast carcinoma treated by radical radiotherapy , 1980, Cancer.

[65]  L. Peters,et al.  Clinical experience with irradiation of inflammatory carcinoma of the breast with and without elective chemotherapy , 1978, Cancer.

[66]  C. Perez-Mesa,et al.  Inflammatory carcinoma of the breast , 1978, Cancer.

[67]  R. Arriagada,et al.  [Breast cancers in the evolutive phase]. , 1978, La Revue du praticien.

[68]  L. Muenz,et al.  Clinical and prognostic features of a rapidly progressing breast cancer in tunisia , 1977, Cancer.

[69]  S. Teitelbaum,et al.  Inflammatory carcinoma of the breast. A Pathologic Definition , 1974, Cancer.

[70]  P. Rosen,et al.  Inflammatory carcinoma of the breast. , 1938, The Surgical clinics of North America.

[71]  C. D. HAAGENSEN,et al.  Diseases of the Breast , 1972 .

[72]  N. Treves.  The inoperability of inflammatory carcinoma of the breast. , 1959, Surgery, gynecology & obstetrics.

[73]  Rogers Cs,et al.  Inflammatory carcinoma of the breast: a critique of therapy. , 1956, Surgery.

[74]  Dockerty Mb,et al.  Inflammatory carcinoma of the breast. , 1948, Surgery, gynecology & obstetrics.

[75]  Carcinoma of the breast. , 1942, Journal of the American Medical Association.

[76]  C. Bell.  A System of Operative Surgery , 1909, Bristol Medico-Chirurgical Journal (1883).